08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Altacor, Proximagen deal

The companies partnered to develop Proximagen's programs targeting the serotonin (5-HT2C) receptor for ophthalmic indications. Altacor will fund preclinical work of PRX00933 , the lead compound under the program, to treat glaucoma. Altacor will receive...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Company News

Ligand, Proximagen deal

Ligand transferred to Proximagen exclusive, worldwide rights to develop and commercialize undisclosed compounds targeting the CXC chemokine receptor 4 ( CXCR4 ; NPY3R ). The compounds are in preclinical development to treat CNS diseases. Ligand...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Company News

Biovitrum, Proximagen deal

Biovitrum completed its previously announced sale of its Cambridge Biotechnology Ltd. subsidiary to Proximagen for an undisclosed percentage of future revenues generated by the subsidiary (see BioCentury, Nov. 2). Biovitrum AB (SSE:BVT), Stockholm, Sweden  ...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

Biovitrum, Proximagen deal

The companies signed a letter of intent for Biovitrum to sell its Cambridge Biotechnology Ltd. subsidiary to Proximagen in exchange for an undisclosed percentage of future revenues generated by the subsidiary. Cambridge's pipeline includes a...
07:00 , Sep 22, 2008 |  BioCentury  |  Strategy

Global reinvention

Biovitrum AB has reinvented itself twice since it was formed in 2001. Last week's deal with Amgen Inc. is directly in line with its latest incarnation as a specialty care-focused biotech that is looking to...
07:00 , Sep 12, 2005 |  BC Week In Review  |  Company News

DanioLabs management update

DanioLabs Ltd. , Cambridge, U.K.   Business: Neurology, Ophthalmic   Hired: Tony Sedgwick as CEO, formerly CEO of Biovitrum AB's Cambridge Biotechnology Ltd. Unit  ...
07:00 , Aug 29, 2005 |  BioCentury  |  Strategy

Biovitrum checks the boxes

Biovitrum AB went from being a Phase II company to a preclinical company after its two lead products failed in 2003 and 2004. Since then, the Swedish company has replenished its pipeline, acquiring several clinical...
07:00 , Aug 29, 2005 |  BioCentury  |  Strategy

Biovitrum's pipeline

Biovitrum's pipeline Biovitrum's pipeline After lead compounds BVT.933 and BVT.3498 (AMG 331) failed in the clinic in 2003 and 2004, Biovitrum set out to fill its pipeline via acquisitions, and early this year set itself...
07:00 , May 2, 2005 |  BC Week In Review  |  Company News

Biovitrum, Cambridge Bio Ltd. deal

Biovitrum completed its previously announced acquisition of Cambridge Biotechnology for an undisclosed sum (see BioCentury, March 28). Biovitrum AB , Stockholm, Sweden   Cambridge Biotechnology Ltd. , Cambridge, U.K.   Business: Metabolic, Neurology, Inflammation  ...
08:00 , Mar 28, 2005 |  BC Week In Review  |  Company News

Biovitrum, Cambridge Bio Ltd. deal

Biovitrum will acquire Cambridge Biotechnology for an undisclosed sum. Cambridge Biotechnology is developing compounds for obesity, pain and inflammation, while Biovitrum develops compounds for metabolic diseases, oncology and ophthalmology. Cambridge Biotechnology's lead compound, CBT 1008,...